KURA earnings

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – – Virtual Kura investor call on June 3 at 8:00 a.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that updated results from the frontline arm of the Phase 1 KOMET-007 (NCT0573518

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceutical company comm

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off Manageable safety and tolerability profile in all RCC patients across multiple dose levels Virtual investor event today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEG

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceuti

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve – – Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone – – Ziftomenib's broad clinical development program spans

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially best-in-class safety profile, once-daily administration, and ease of co-administration with common supportive medications in adult patients with R/R NPM1-mutated AML – – KOMZIFTI approval granted with no Boxed Warning related to QTc prolongation or Torsades de Pointes – – Kura Oncology will host a

– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemotherapy in frontline and R/R NPM1-m AML – – Clinical data at ESMO 2025 Congress highlight promise of second strategic program – FTIs darlifarnib and tipifarnib show promising safety profile

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the investor relations section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a clin

FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% objective response rate and 80% disease control rate in renal cell carcinoma (RCC) cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT / 1:30 p.m. ET / 7:30 p.m. CEST SAN DIEGO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise

– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to supp

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ2. A live webcast and archived rep

– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the confer

– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track for 2Q 2025 – – Registrational KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated approval and full approval – – Registrational KOMET-017-NIC trial of venetoclax / azacitidine combination will assess CR and OS as dual-primary endpoints to support potential U.S. accelerated approval and full approval – – KOMET-017-IC and NIC Phase 3 trials expected to initiate in 2H 2025 – – Multiple clin

– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively – – Promising clinical activity in R/R NPM1-m and KMT2A-r AML with ven/aza, including ven-experienced patients – – Ziftomenib generally well tolerated in combination with standards of care at all dose levels studied – – Kura Oncology to host virtual investor event today at 8:00 a.m. ET – SAN DIEGO and TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE:

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to

– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/aza in R/R AML and 7+3 in 1L adverse risk AML to be presented at ASH – – Phase 1b expansion study of ziftomenib in combination with standards of care now enrolling at 600 mg in all cohorts – – Preclinical data support opportunity for ziftomenib in GIST; proof-of-concept study expected to begin in 1H 2025 – – First patient dosed in study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $455.3 million in cash, cas

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast a

– Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – – Data from 100 patients in KOMET-007 trial of ziftomenib in combination with ven/aza and 7+3 expected in Q4; Phase 1b expansion study in 1L AML now enrolling – – Investigational New Drug (IND) application cleared for ziftomenib in GIST – – Preclinical data at ADA support potential for menin inhibitor in diabetes – – First patient dosed in study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $491.5 million in cash, cash equivalents and investments provide runway into 2027 – – Management

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (877) 300-8521 for domestic callers and (412) 317-6026 for international callers. A live webcast and archived replay of the event will be

– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precisio

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be ava

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of th

– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 – – First patient dosed in FIT-001 dose-escalation study of next-generation FTI, KO-2806 – – Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $452.6 million in cash, cash equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2023 financial results after the close of U.S. financial markets on Thursday, August 3, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be

– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients in the second quarter of 2023 – – Preclinical data highlighting potential use of FTIs in combination with multiple targeted therapies presented at AACR – – IND for KO-2806, a next-generation FTI, cleared by FDA – – $406 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be ava

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA – – $25 million strategic equity investment from Bristol Myers Squibb – – $438 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb.

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.  To participate in the teleconference, domestic callers should dial 1-877-407-4018 and international callers should dial 1-201-689-8471. A live webcast of the call can b

– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN trial of tipifarnib in HRAS mutant HNSCC closed to further enrollment – – $25 million equity investment from Bristol Myers Squibb and $125 million term loan facility from Hercules Capital – – $428 million in cash plus equity investment and term loan facility, if fully drawn, provide runway into 2026 – – Management to host webcast and conference call today at 8:00 a.m. ET – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutica

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura's management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.  To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807. A live webc

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort – – $450 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.  To participate in the teleconference, domestic callers should dial 1-888-882-4478 and international callers should dial 1-323-794-2590 and reference conference ID: 8696904. A li

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohort expected by third quarter – – First patient in Phase 1 KURRENT-LUNG trial of tipifarnib plus osimertinib expected in third quarter – – $480 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharm

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (844) 826-3035 for domestic callers and (412) 317-5195 for international callers and entering the conference code: 10166202. A live webcast

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC – – Abstract supporting next-generation FTI program accepted for presentation at AACR – – $518 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 864562

SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. The partial clinical hold was initiated following the Company's recent report to the FDA of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.

– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic activity in combination with venetoclax – – First clinical site activated in Phase 1/2 trial of tipifarnib plus alpelisib in HNSCC – – $543.4 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promis

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (866) 269-4260 for domestic callers and (323) 347-3277 for international callers and entering the conference code: 9395801. A live webcas

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program – – $567.5 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today re

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 3171857. A live webcast